Rizatriptan
- Generic Name
- Rizatriptan
- Brand Names
- Maxalt, Rizaport
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N5
- CAS Number
- 144034-80-0
- Unique Ingredient Identifier
- 51086HBW8G
- Background
Rizatriptan is a second-generation triptan and a selective 5-HT receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
- Indication
Rizatriptan is indicated for the acute treatment of diagnosed migraine with or without aura. Rizatriptan is not indicated for the prophylactic therapy of migraine nor the treatment of cluster headache.
...
- Associated Conditions
- Migraine With Aura, Migraine Without Aura, Migraine with acute onset aura
- Associated Therapies
- Acute Treatment of Migraine
Maximizing Outcomes in Treating Acute Migraine
- Conditions
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 1594
- Registration Number
- NCT03896009
- Locations
- 🇺🇸
Clinical Research Site, Seattle, Washington, United States
Rizatriptan for Episodic Dizziness in Vestibular Migraine
- Conditions
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Robert W. Baloh
- Target Recruit Count
- 223
- Registration Number
- NCT02447991
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸ICAHN School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops
- Conditions
- Interventions
- Locations
- 🇺🇸
Madigan Army Medical Center - Neurology Clinic, Tacoma, Washington, United States
Rizatriptan 10 MG RPD in the Treatment of Acute Migraine
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Universität Duisburg-Essen
- Target Recruit Count
- 195
- Registration Number
- NCT01057160
- Locations
- 🇩🇪
Department of Neurology, University Hospital Essen, Essen, Germany
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1382
- Registration Number
- NCT01001234
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 109
- Registration Number
- NCT00894556
Two Rizatriptan Prescribing Portions for Treatment of Migraine
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2010-06-08
- Lead Sponsor
- Clinvest
- Target Recruit Count
- 197
- Registration Number
- NCT00397254
- Locations
- 🇺🇸
Clinvest, Springfield, Missouri, United States
🇺🇸Physician Associates, Oviedo, Florida, United States
🇺🇸Thomas Jefferson University Hospital Jefferson Headache Center, Philadelphia, Pennsylvania, United States
Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 36
- Registration Number
- NCT00360282
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 420
- Registration Number
- NCT00246337
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.